Drug Database
TL

TLX007-CDx (TLX007 CDx / TLX007CDx)

✓ Approved

Telix Pharmaceuticals Limited · Imaging Agents · Imaging Agents

What is TLX007-CDx?

TLX007-CDx is a imaging agents developed by Telix Pharmaceuticals Limited. It is approved for therapeutic indications via unknown.

Drug Profile

Brand NamesTLX007 CDx, TLX007CDx
CompanyTelix Pharmaceuticals Limited
Drug ClassImaging Agents
RouteUnknown
StatusApproved

Therapeutic Indications

TLX007-CDx is developed for 2 unique indications across 1 therapeutic area.

Therapeutic AreaConditionPhase
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Prostate cancer✓ Approved
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Uterine cancerBLA/NDA

Related Research Articles

PubMedIJU case reports2026-06-08

Significant Response to Nivolumab Plus Ipilimumab in Metastatic Mucinous Tubular and Spindle Cell Carcinoma: A Case Report.

Shimasaki Sho S, Yamamoto Shinkuro S, Iguchi Mitsuko M, Yamashita Erika E et al.

Mucinous tubular and spindle cell carcinoma (MTSCC) is a rare renal cell carcinoma subtype that is typically indolent but may exhibit aggressive behavior. No standard systemic therapy has been established for metastatic MTSCC. A 71-year-old woman underwent retroperitoneoscopic radical left nephrectomy for MTSCC (pT1b). Six months later, computed tomography (CT) and 18F-fluorodeoxyglucose positron emission tomography (PET)/CT revealed lung, bone, and adrenal metastases. Bone biopsy confirmed metastatic MTSCC, and the patient was classified as poor risk. Combination therapy with nivolumab and ipilimumab was initiated. After two cycles, PET/CT showed marked regression of metastatic lesions (SUVmax decreased from 21.7 to 4.3). RECIST evaluation demonstrated a partial response. Genomic profiling revealed microsatellite stability and a low tumor mutational burden, with no clinically actionable alterations identified on FoundationOne CDx. No disease progression was observed at 9 months. This case demonstrates the potential efficacy of combination immunotherapy in aggressive metastatic MTSCC.

PubMedCell death & disease2026-06-06

The CDK4/6 inhibitor dalpiciclib augments the antitumor efficacy of enzalutamide in preclinical models of castration-resistant prostate cancer through inhibition of MCM4-mediated DNA replication.

Liu Yue Y, Ke Yuan Y, Yu Jingtian J, Chai Mengting M et al.

Castration-resistant prostate cancer (CRPC) is a fatal malignancy often associated with alterations in cell cycle regulation, particularly within the Cyclin/CDK/RB axis. Despite ongoing clinical trials assessing CDK4/6 inhibitors in prostate cancer, clinical evidence remains limited. Although the androgen receptor (AR) inhibitor enzalutamide (ENZ) initially demonstrates therapeutic efficacy, resistance develops over time, and monotherapy offers limited antitumor benefits, highlighting the need for effective combination therapies. In this study, pharmacological profiling, genetic dependency analysis, RNA sequencing, and functional validation were conducted across various in vitro and in vivo preclinical CRPC models. The combination of ENZ and the CDK4/6 inhibitor dalpiciclib (DAL) exhibited potent antitumor activity in CRPC cell lines, a cell-derived xenograft (CDX) model, and a lymphatic metastatic model. Moreover, ENZ plus DAL inhibited cell cycle progression, migration, and DNA replication, while promoting apoptosis in CRPC cells. Mechanistically, ENZ blocked AR-mediated transcriptional activation of MCM4, a critical component of the DNA helicase complex, thereby enhancing the effect of CDK4/6 inhibition on DNA replication and inducing a pronounced synergistic antitumor response. These results suggest that the ENZ-DAL combination is a promising therapeutic approach that warrants further clinical evaluation in CRPC patients.

PubMedbioRxiv : the preprint server for biology2026-06-04

Fast pairwise coalescence enables gene-resolution scans for recent selection in diverse human populations.

Korfmann Kevin K, Mathieson Sara S

Identifying the genetic changes that shaped recent human adaptation depends on our ability to detect selection from genomic data. Summary statistics from haplotype scans have been widely used for that purpose, aggregating genetic signal over windows, though resolution is limited by linkage and their power may diminish as sweeps approach fixation, as in the case of the integrated haplotype score (iHS). Ancient DNA based scans recover signal by analysing time-series trajectories, but the majority of human populations fall outside the geographic range of any existing ancient DNA dataset. Pairwise coalescence times provide a way to complement statistics and can be applied to any modern cohort, yet computing them densely enough at cohort scale poses a computational challenge due to the quadratic growth in the number of haplotype pairs. We introduce gamma_smc_cu , a GPU implementation of the Gamma-SMC algorithm (Schweiger and Durbin, 2023) for pairwise time-to-the-most-recent-common-ancestor (TMRCA) inference. Applied to the 1000 Genomes Project (3,202 phased samples, corresponding to 6,404 haplotypes; 829,638 within-population pairs across 26 populations and five different continental ancestries; ∼10 12 per-site posterior evaluations), it yields a gene-level TMRCA landscape of 17,823 autosomal protein-coding genes after masking for segmental duplications. The scan recovers well-known sweeps ( LCT, SLC24A5, EDAR, FADS1, HERC2, ABCC11 ) and, combined with a depleted-to-enriched variant-class profile, resolves haplotype-block signals down to the gene level. Of seven case studies, two are developed in the main text - GRK2 / ADRBK1 (chr11q13.2; SAS+EUR) and TREML1 / TREM2 (chr6p21.1) - and the remaining five ( IFIH1 chr2q24/IBS, CCDC92 chr12q24/CDX, SLC6A15 chr12q21/CHS, BPIFA2 chr20q11/GIH, CLEC6A chr12p13/CDX) are presented in the Supplementary Information (SI). Notably, TREML1 / TREM2 is a shared out-of-Africa signal - ranked below the within-population 1% tail in 16 of 19 non-African 1000 Genomes panels that PopHumanScan and five landmark haplotype-based scans miss. A previous 10 kb-windowed-mean iHS scan dilutes the cluster of extreme sites packed inside the ∼5 kb gene bodies, while our own gene-level iHS independently recovers the locus in three South Asian panels (BEB, STU, ITU; top 0.4% genome-wide). We cross-validate the seven cases against the 9.7 million per-variant selection posteriors from a recent West-Eurasian ancient DNA scan. BPIFA2 is detected concordantly ( s ≈ 1.8% per generation). GRK2 and CCDC92 reach detection threshold in flanking variants but not within their own gene bodies, while the TREML1 / TREM2 cluster falls below it. To calibrate novelty, we review the candidate landscape against an expanded eight-catalog set spanning curated haplotype scans, the largest current West-Eurasian ancient-DNA leads, and a recent 26-population iHS refinement; the vast majority of our loci overlap at least one prior entry, and only a handful - including TREML1 / TREM2 - remain unflagged. The contributions of this work are gene-level resolution, systematic ancient DNA cross-validation, and a reusable TMRCA landscape that complements aDNA panels.

PubMedScience translational medicine2026-06-03

Claudin-1 targeting suppresses tumor growth, invasion, and metastasis in patient-derived cholangiocarcinoma models.

Nehme Zeina Z, Muller Marion M, Brochon Jade J, Crouchet Emilie E et al.

Cholangiocarcinoma (CCA) is an adenocarcinoma of the hepatobiliary system that has recently risen in incidence and mortality with unsatisfactory treatment options. Claudin-1 (CLDN1) is a transmembrane protein expressed in tight junctions and exposed on the cell surface in liver fibrosis and cancer. Using single-cell RNA sequencing (scRNA-seq) and spatial transcriptomics of tissues of patients with CCA, we show that CLDN1 expression is up-regulated in cancer cells and is associated with stemness and cell fate. Genetic gain-of-function studies in CCA orthotopic in vivo mouse models showed decreased survival and enhanced tumor growth, unraveling a functional role of CLDN1 as an oncogenic driver. Targeting exposed nonjunctional CLDN1 using highly specific CLDN1 monoclonal antibodies (mAbs) inhibited tumor growth across CCA CDX and PDX mouse models and patient-derived CCA organoids, including tumors with medium or low CLDN1 expression. Moreover, antibody treatment inhibited tumor cell migration, invasion, and extrahepatic metastasis. Mechanistically, targeting exposed cell surface CLDN1 on CCA tumors using mAbs inhibited Notch1 and TROP2/STAT3 signaling pathways, resulting in decreased cancer cell stemness and epithelial-to-mesenchymal transition. Loss-of-function studies using CRISPR-Cas9 and RNAi combined with rescue and confocal imaging studies confirmed the functional and mechanistic role of these pathways. In conclusion, these results uncover CLDN1 as a previously undiscovered CCA driver and therapeutic target, paving the way for the clinical development of CLDN1 mAbs to improve the dismal outcome of patients with advanced CCA.

PubMedOtolaryngologia polska = The Polish otolaryngology2026-06-01

Genetic mutations in metastatic adenocarcinoma of unknown primary.

Nagano Hiromi H, Kiyama Satoshi S, Kyutoku Takayuki T, Matsumoto Hayato H et al.

Although several genomic alterations have been reported in adenocarcinoma of unknown primary (ACUP), molecularly targeted therapies are not yet clinically established, and comprehensive genomic profiling (CGP) is rarely used in daily practice. We aimed to clarify the molecular landscape and prognostic impact of key mutations in recurrent or metastatic ACUP. Data from 480 consecutive ACUP patients registered in Japan's National Cancer Center (C-CAT) between June 2019 and August 2025 were analyzed. Somatic mutations were identified using the FoundationOne CDx platform. Overall survival (OS) was assessed by Kaplan-Meier analysis, log-rank tests, and multivariate Cox proportional hazards modeling. The most frequent alterations were TP53 (59.4%), KRAS (31.5%), CDKN2A (26.3%), KMT2D (22.3%), LTK (17.9%), NOTCH3 (16.9%), STK11 (16.3%), CDKN2B (15.8%), ERBB2 (15.4%), and GNAS (15.2%). Patients harbored an average of 17.3 9.9 mutations. Mutations in GNAS (p = 0.046) and PIK3CA (p = 0.025) were associated with better OS, whereas ARID1A (p = 0.049) and NOTCH1 (p = 0.038) predicted worse OS. In Cox analysis, hazard ratios (HR [95% CI]) were 0.57 (0.36-0.92, p = 0.020) for GNAS, 0.57 (0.33-0.96, p = 0.033) for PIK3CA, 1.98 (1.27-3.09, p = 0.0024) for ARID1A, and 1.84 (1.17-2.91, p = 0.0090) for NOTCH1. GNAS and PIK3CA mutations were linked to favorable outcomes, while ARID1A and NOTCH1 alterations indicated poor prognosis in ACUP. These results highlight the prognostic significance of specific genomic alterations and support integrating CGP into the clinical management of ACUP.

PubMedMolecular cancer therapeutics2026-05-31

Molecular Design and Preclinical Evaluation of GenSci143, a Novel B7-H3- and PSMA-Directed Bispecific Antibody-Drug Conjugate, for the Treatment of Prostate Cancer.

Xu Yao Y, Li Fu F, Cui Zhiyu Z, Xie Hongmei H et al.

Antibody-drug conjugate (ADC) has rapidly transformed the treatment landscape for solid tumors; however, due to heterogeneity in target antigen expression, suboptimal efficacy and emergence of acquired resistance present significant challenges to the development of curative ADCs for cancers. Here, we report the preclinical evaluation of GenSci143, a novel B7-H3 × PSMA-directed bispecific ADC (BsADC), designed to overcome tumor antigen heterogeneity-associated drug resistance for the treatment of metastatic castration-resistant prostate cancer (mCRPC). GenSci143 comprises a highly active topoisomerase 1 inhibitor payload conjugated to a dual-targeting antibody via a plasma-stable linker to minimize off-target toxicity. Gene profiling analysis reveals high co-expression of B7-H3 and PSMA in prostate cancer (PCa), laying the biological basis of dual targeting strategy. In vitro, GenSci143 exhibited strong binding, efficient internalization, and potent cytotoxicity against PCa cells expressing either or both target antigens, as well as a robust bystander killing effect, outperformed single-target benchmark ADCs that are currently in clinical development. In multiple cancer cell line-derived and patient-derived xenograft (CDX/PDX) models of PCa, GenSci143 induced profound tumor regression and demonstrated superior antitumor activity vs. competitor ADCs. Furthermore, GenSci143 displayed excellent plasma stability and favorable pharmacokinetic properties in non-human primates. The compelling preclinical efficacy across cancer models with varying levels of target antigen expression and its exceptional plasma stability support the translational relevance of GenSci143. These results indicate that GenSci143 is a promising therapeutic candidate for castration resistant PCa and potentially other malignancies, warranting its further clinical development.

+2186 more articles available with a free account

Sign up free to view all articles →

Ask about TLX007-CDx